Hae Naem Kwon

Title: Hae Naem Kwon: Innovator in Cancer Therapeutics

Introduction

Hae Naem Kwon is a notable inventor based in Yongin-si, South Korea. He has made significant contributions to the field of biomedical research, particularly in the development of innovative therapeutic agents for cancer treatment.

Latest Patents

Hae Naem Kwon holds a patent for a bispecific antibody specifically binding to GPNMB and CD3. This bispecific anti-GPNMB/anti-CD3 antibody demonstrates high affinity and specificity to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B). The patent outlines the use of this antibody to induce death in cancer cells expressing GPNMB while inhibiting their proliferation. As a result, this bispecific antibody has the potential to serve as an effective therapeutic agent for cancers that express GPNMB.

Career Highlights

Throughout his career, Hae Naem Kwon has worked with reputable organizations, including the Green Cross Corporation and the Mogam Institute for Biomedical Research. His work has focused on advancing cancer treatment through innovative research and development.

Collaborations

Hae Naem Kwon has collaborated with several professionals in his field, including Jae Chan Park and Eun Jung Song. These collaborations have contributed to the advancement of his research and the development of new therapeutic strategies.

Conclusion

Hae Naem Kwon's innovative work in developing bispecific antibodies highlights his commitment to improving cancer treatment. His contributions to biomedical research are paving the way for new therapeutic options for patients.